Abstract
Introduction and ObjectivesOmalizumab is indicated as add-on therapy to improve asthma control in children aged ≥6 years with severe persistent allergic asthma.1 In the UK, only children with the most...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
